Dosing schedule for AFM13 and pembrolizumab as combination therapy
| . | AFM13 dose levels (mg/kg) . | Pembrolizumab (mg) . | ||
|---|---|---|---|---|
| . | Weeks 2 and 3 . | Weeks 4-9 . | Weeks 10, 13, 16, 19, 22, 25 . | Weeks 1-52 Q3W* . |
| Cohort 1 | 0.1 × 3 | 0.5 | 0.5 | 200 |
| Cohort 2 | 0.5 × 3 | 1.5 | 1.5 | 200 |
| Cohort 3 | 3.0 × 3 | 7.0 | 7.0 | 200 |
| . | AFM13 dose levels (mg/kg) . | Pembrolizumab (mg) . | ||
|---|---|---|---|---|
| . | Weeks 2 and 3 . | Weeks 4-9 . | Weeks 10, 13, 16, 19, 22, 25 . | Weeks 1-52 Q3W* . |
| Cohort 1 | 0.1 × 3 | 0.5 | 0.5 | 200 |
| Cohort 2 | 0.5 × 3 | 1.5 | 1.5 | 200 |
| Cohort 3 | 3.0 × 3 | 7.0 | 7.0 | 200 |
Q3W, once every 3 weeks.
Until disease progression, unacceptable toxicity, cessation of treatment because of complete response (at investigator’s discretion) or 52 weeks of treatment, whichever occurred first.